|
A phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
|
Stock and Other Ownership Interests - BeiGene (I) |
|
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
Employment - Acceleron Pharma; BeiGene; Infinity Pharmaceuticals |
Stock and Other Ownership Interests - Acceleron Pharma; BeiGene; Infinity Pharmaceuticals |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |